

Article

Not peer-reviewed version

# Hispidulin inhibits vascular inflammation triggered by *Porphyromonas gingivalis* lipopolysaccharide

Yeon Kim , Hoyong Lee , Hyun-Joo Park , Mi-Kyoung Kim , [Yong-Il Kim](#) , [Hyung Joon Kim](#) , [Soo-Kyung Bae](#) , [Yung-Jin Kim](#) <sup>\*</sup> , [Moon-Kyoung Bae](#) <sup>\*</sup>

Posted Date: 5 September 2023

doi: 10.20944/preprints202309.0155.v1

Keywords: Hispidulin; *Porphyromonas gingivalis*; lipopolysaccharide; vascular endothelial cells; vascular inflammation



Preprints.org is a free multidiscipline platform providing preprint service that is dedicated to making early versions of research outputs permanently available and citable. Preprints posted at Preprints.org appear in Web of Science, Crossref, Google Scholar, Scilit, Europe PMC.

Copyright: This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

## Article

# Hispidulin Inhibits Vascular Inflammation Triggered by *Porphyromonas gingivalis* Lipopolysaccharide

Yeon Kim <sup>1,2,3,†</sup>, Hoyong Lee <sup>4,†</sup>, Hyun-Joo Park <sup>1,2,3</sup>, Mi-Kyoung Kim <sup>1</sup>, Yong-Il Kim <sup>4</sup>,  
Hyung Joon Kim <sup>1,2,3</sup>, Soo-Kyung Bae <sup>3,5</sup>, Yung-Jin Kim <sup>6,\*</sup> and Moon-Kyoung Bae <sup>1,2,3,\*</sup>

<sup>1</sup> Department of Oral Physiology, School of Dentistry, Pusan National University, Yangsan, South Korea; graceyeon88@gmail.com (Y.K.); phj3421@hanmail.net (H.J.P.); eenga@naver.com (M.K.K.); hjoonkim@pusan.ac.kr (H.J.K.)

<sup>2</sup> Periodontal Disease Signaling Network Research Center (MRC), Pusan National University, Yangsan, South Korea

<sup>3</sup> Dental and Life Science Institute, Pusan National University, Yangsan, South Korea; skbae@pusan.ac.kr (S.K.B.)

<sup>4</sup> Department of Orthodontics, School of Dentistry, Pusan National University, Yangsan, South Korea; hoyoungl@hanmail.net (H.L.); kimyougil@pusan.ac.kr (Y.I.K.)

<sup>5</sup> Department of Dental Pharmacology, School of Dentistry, Pusan National University, Yangsan, South Korea

<sup>6</sup> Department of Molecular Biology, Pusan National University, Busan 46241, South Korea

\* Correspondence: mkbae@pusan.ac.kr (M.K.B.); yjinkim@pusan.ac.kr (Y.J.K.)

† These authors contributed equally to this work.

**Abstract:** Hispidulin is a natural bioactive flavonoid that has been studied for its potential therapeutic properties, including its anti-inflammatory, antioxidant, and neuroprotective effects. The aim of this study was to explore whether hispidulin could inhibit endothelial inflammation triggered by *Porphyromonas gingivalis* (*P. gingivalis*) lipopolysaccharide (LPS). The adhesion of monocytes to vascular endothelium was evaluated by *in vitro* and *ex vivo* monocyte adhesion assays. We analyze the migration of monocytes across the endothelial layer using transmigration assay. The result showed that treatment with hispidulin decreased *P. gingivalis* LPS-induced the adhesion of monocytes to endothelial cells and their migration by suppressing *P. gingivalis* LPS-triggered expression of intercellular adhesion molecule-1 (ICAM-1) through downregulating nuclear factor- $\kappa$ B (NF- $\kappa$ B). In addition, hispidulin inhibited *P. gingivalis* LPS-induced mitogen-activated protein kinases (MAPKs) and AKT in endothelial cells. Altogether, the results indicate that hispidulin suppresses vascular inflammation induced by *P. gingivalis* LPS. Mechanistically, it prevents the adhesion of monocytes to the vascular endothelium and migration and inhibits NF- $\kappa$ B, MAPKs, and AKT signaling in endothelial cells.

**Keywords:** hispidulin; *Porphyromonas gingivalis*; lipopolysaccharide; monocyte; vascular endothelial cells; vascular inflammation

## 1. Introduction

Periodontal disease is a frequent inflammatory disorder within the oral cavity, affecting the teeth and tooth-supporting tissues, and it is caused primarily by *P. gingivalis*, a major gram-negative anaerobic periodontal pathogen [1,2]. Growing evidence indicates that periodontal disease has an adverse impact on several systemic diseases, including diabetes, Alzheimer's, colorectal cancer, and atherosclerosis [3]. *P. gingivalis* and its LPS can cause periodontitis and directly lead to systemic inflammation by invading the bloodstream, which may trigger or exacerbate vascular inflammatory processes, especially atherosclerosis [4].

Flavonoids are plant-derived polyphenolic compounds with various beneficial effects in relieving the initiation and progression of periodontal disease [5]. Administration of epigallocatechin-3-gallate, the major flavonoid in green tea, to apolipoprotein E (ApoE)-knockout mice injected with *P. gingivalis* decreased atherosclerotic plaque formation and serum levels of pro-inflammatory cytokines and atherosclerotic risk factors [6]. Hispidulin (4',5,7-trihydroxy-6-


methoxyflavone) is a natural phenolic flavonoid present in various plants, including *Saussurea involucreata*, *Arrabidaea chica*, *Salvia involucreata*, and *Grindelia argentina*, and it has various pharmacological activities, including antioxidant, anticancer, antifungal, anti-osteoporotic, neuroprotective, and anti-inflammatory activities [7–10]. Hispidulin alleviates skin, airway, and allergic inflammation by downregulating the production of pro-inflammatory cytokines and chemokines [11,12]. More recently, hispidulin has been shown to block the angiogenic properties of endothelial cells, such as vascular endothelial growth factor-induced proliferation, migration, and tubular formation [13]. However, little attention has been given to the inhibitory effect of hispidulin on vascular inflammation.

The aim of this study was to determine whether hispidulin prevented *P. gingivalis* LPS-induced endothelial inflammation and propose possible anti-inflammatory mechanisms of hispidulin in endothelial cells.

## 2. Results

### 2.1. Hispidulin decreases *P. gingivalis* LPS-induced expression of inflammatory cytokines in vascular endothelial cells


To determine the optimal concentration of hispidulin for *in vitro* experiments, we assessed the viability of human umbilical vein endothelial cells (HUVECs) HUVECs treated with different concentrations of hispidulin (1, 5, 10, or 20  $\mu$ M) for 1–3 days using the methylthiazolyl tetrazolium (MTT) assay (MTT) assay. No cytotoxicity was observed when cells were treated with 1  $\mu$ M hispidulin. At 5  $\mu$ M or 10  $\mu$ M, hispidulin slightly decreased the relative viability over 3 days. After 2–3 days of treatment with 20  $\mu$ M hispidulin, the proliferation of HUVECs was significantly reduced (approximately 20 %) compared to that in the control group (Figure 1a). During vascular inflammation, pro-inflammatory cytokines, such as monocyte chemoattractant protein-1 (MCP-1), Interleukin-1  $\beta$  (IL-1 $\beta$ ), and Interleukin-8 (IL-8), play critical roles in the recruitment of monocytes to endothelial cells at inflammation sites [14]. Hispidulin treatment decreased the mRNA levels of MCP-1, IL-1 $\beta$ , and IL-8 upregulated by *P. gingivalis* LPS (Figure 1b)



**Figure 1. Effect of hispidulin on the expression of pro-inflammatory cytokines in HUVECs.** (a) HUVECs were exposed to different concentrations of hispidulin for the indicated times. After treatment, cell proliferation was evaluated using the MTT assay. \* $p < 0.01$  compared to that in control. (b) HUVECs were treated with *P. gingivalis* LPS (5  $\mu$ g/mL) alone or in combination with hispidulin (5  $\mu$ M) for 16 h. The expression of MCP-1, IL-1 $\beta$ , and IL-8 was analyzed using real-time quantitative PCR. The level in the controls was set to 1.0, and the values were normalized to  $\beta$ -actin. \* $p < 0.01$  compared to that in control. # $p < 0.01$  compared to that in *P. gingivalis* LPS.

## 2.2. Hispidulin decreases *P. gingivalis* LPS-induced expression of ICAM-1 in endothelial cells

Vascular endothelial cells express the cell adhesion molecules such as ICAM-1 in response to injury or inflammation, thereby allowing for the adhesion of leukocytes to the endothelium [15]. To determine the potential role of hispidulin in endothelial dysfunction, we examined its effect on *P. gingivalis* LPS-induced ICAM-1. *P. gingivalis* LPS significantly increased ICAM-1 mRNA levels in HUVECs; however, treatment with hispidulin reduced their expression (Figure 2a). As shown in Figure 2b, western blot showed hispidulin decreases the ICAM-1 protein levels induced by *P. gingivalis* LPS. In addition, surface expression of ICAM-1 protein was evaluated using flow cytometry. Hispidulin reduced *P. gingivalis* LPS-induced cell surface expression of ICAM-1 protein (Figure 2c).




**Figure 2. Hispidulin reduces ICAM-1 expression in *P. gingivalis* LPS-induced HUVECs.** (a, b) HUVECs were incubated with *P. gingivalis* LPS (5 µg/mL) alone or in combination with hispidulin (5 µM) for 16 h, and the expression of ICAM-1 was analyzed using real-time quantitative PCR (a) and western blotting (b). The level in the controls was set to 1.0, and the values were normalized to β-actin (a) or α-tubulin as the loading control (b). \*p < 0.01 compared to that in control. #p < 0.01 compared to that in *P. gingivalis* LPS. (c) HUVECs were treated with *P. gingivalis* LPS alone or in combination with 5 µM hispidulin for 16 h. ICAM-1 (CD54) was quantified using flow cytometry.

## 2.3. Hispidulin inhibits monocyte adhesion to *P. gingivalis* LPS-stimulated vascular endothelial cells

Next, we investigated whether hispidulin affected the adhesion of monocytes to *P. gingivalis* LPS-stimulated endothelial cells, which is a critical step in vascular inflammation [16]. *P. gingivalis* LPS stimulated the adhesion of THP-1 cells to HUVECs; however, this effect decreased significantly upon treatment of HUVECs with hispidulin (Figure 3a). Next, we conducted an *ex vivo* endothelial-monocyte adhesion assay using fluorescently labeled THP-1 cells and the aorta isolated from a Sprague-Dawley rat. The number of fluorescently-labeled monocytes adhering to the aortic endothelium increased significantly following *P. gingivalis* LPS treatment relative to the untreated control (Figure 3b); however, it dropped significantly upon hispidulin addition.

2.4. Hispidulin decreases the *P. gingivalis* LPS-induced transendothelial migration of monocytes

Once monocytes adhere to the endothelium, they transmigrate through the endothelial layer as a subsequent progressive step in atherosclerotic lesion formation [17,18]. We used a transmigration assay to assess whether the migration of *P. gingivalis* LPS-stimulated THP-1 cells through the endothelial cell layer was modulated by hispidulin treatment. We observed that *P. gingivalis* LPS increased significantly (by 7-fold) the transmigration of THP-1 cells across HUVEC monolayers relative to control cells (Figure 3c); however, it was markedly retarded by hispidulin (Figure 3c).



**Figure 3.** Hispidulin decreases *P. gingivalis* LPS-induced monocytes adhesion to endothelium *in vitro* and *ex vivo* and transendothelial migration of monocytes. (a) HUVECs were incubated with *P. gingivalis* LPS (5 µg/mL) alone or in combination with hispidulin (5 µM) for 16 h. Calcein-AM-labeled


THP-1 cells (green) were identified using fluorescence microscopy at 40× magnification. The average number of adherent monocytes was calculated in three fields for each set of four wells and normalized to the control group. \* $p < 0.01$  compared to that in control. \* $p < 0.01$  compared to that in *P. gingivalis* LPS. (b) The aorta isolated from Sprague-Dawley rats was treated with *P. gingivalis* LPS (5  $\mu\text{g/mL}$ ) alone or in combination with hispidulin (5  $\mu\text{M}$ ) for 16 h. At the end of incubation, THP-1 cells were stained with calcein-AM for 30 min and then observed using fluorescence microscopy at 40× magnification. \* $p < 0.01$  compared to that in control. \* $p < 0.01$  compared to that in *P. gingivalis* LPS. (c) To examine THP-1 cells passed through endothelial cells into the lower chamber, HUVECs were treated with *P. gingivalis* LPS (5  $\mu\text{g/mL}$ ) in the presence or absence of hispidulin for 24 h and co-cultured with calcein-AM-labeled THP-1 monocytes in the upper chamber of transwells. The number of THP-1 cells (green) in the lower chamber of the transwell was counted from randomly acquired images (40× magnification). \* $p < 0.01$  compared to that in control. \* $p < 0.01$  compared to that in *P. gingivalis* LPS.

#### 2.5. Hispidulin downregulates *P. gingivalis* LPS-induced transcriptional activation of ICAM-1 through NF- $\kappa\text{B}$ activation

NF- $\kappa\text{B}$  mediates the induction of pro-inflammatory cytokines and cell adhesion molecules, thereby leading to pro-inflammatory responses in vascular endothelial cells [19]. ICAM-1 promoter has binding sites for NF- $\kappa\text{B}$ . We performed luciferase promoter assays to determine whether hispidulin regulated ICAM-1 transcriptional activity. The full-length promoter regions of ICAM-1 (1.3 kb) in the luciferase reporter construct contained the NF- $\kappa\text{B}$ , TRE, and GATA binding sites [20]. ICAM-1 truncated promoter construct contained a proximal NF- $\kappa\text{B}$  binding motif (Figure 4a). Whereas *P. gingivalis* LPS enhanced the reporter activity of truncated ICAM-1 promoter; this increase was attenuated by hispidulin treatment (Figure 4a). These results were similar to those obtained with the full-length ICAM-1 promoter, indicating that NF- $\kappa\text{B}$  binding site played an essential role in mediating the effect of hispidulin on *P. gingivalis* LPS-activated promoters. Inflammatory stimuli promote the translocation of the p65 subunit of NF- $\kappa\text{B}$  into the nucleus and its subsequent binding to cognate DNA-binding sites to upregulate several inflammation-related genes [21]. Immunocytochemical analysis demonstrated the localization of p65 within the nucleus of HUVECs after *P. gingivalis* LPS stimulation. In contrast, exposure to *P. gingivalis* LPS and hispidulin decreased nuclear p65 accumulation (Figure 4b).

#### 2.6. Hispidulin downregulates *P. gingivalis* LPS-induced MAPKs and AKT in vascular endothelial cells

*P. gingivalis* LPS triggers MAPKs signaling, including extracellular signal-regulated kinase (ERK), c-Jun N-terminal kinase (JNK) and p38MAPK in human gingival fibroblasts, leading to increased cytokine production [22]. The AKT signaling pathway plays an important role in regulating the survival of human gingival epithelial cells [23]. We examined the impact of hispidulin on the MAPKs and AKT pathways in *P. gingivalis* LPS-stimulated endothelial cells. The addition of hispidulin reduced the *P. gingivalis* LPS-stimulated phosphorylation of ERK, p38MAPK, and JNK and significantly inhibited that of AKT in HUVECs (Figure 4c).



**Figure 4. Hispidulin inhibits *P. gingivalis* LPS-induced NF-κB-dependent ICAM-1 promoter activity and MAPKs and AKT signalings.** (a) HUVECs were transiently transfected with the full-length and truncated promoters of the ICAM-1 genes. Transfected HUVECs were treated with *P. gingivalis* LPS (5 μg/mL) alone or in combination with hispidulin (5 μM) for 16 h. \*p < 0.01 compared to that in control. #p < 0.01 compared to that in *P. gingivalis* LPS. (b) HUVECs were pretreated with hispidulin (5 μM) for 30 min and then incubated for 1 h with *P. gingivalis* LPS (5 μg/mL). NF-κB p65 (green) localization in the nuclei (blue) was observed. (c) HUVECs were pretreated for 30 min with or without hispidulin (5 μM) before stimulation with *P. gingivalis* LPS (5 μg/mL) for 10 min. Western blots were probed with anti-phospho-ERK, anti-ERK, anti-phospho-p38MAPK, anti-p38MAPK, anti-phospho-JNK, anti-JNK, anti-phospho-AKT, and anti-AKT antibodies. α-tubulin served as the loading control.

### 3. Discussion

Hispidulin is a natural flavonoid with appealing anti-inflammatory, antioxidant, neuroprotective, anticancer, anti-diabetic, and anti-microbial activities and exerts beneficial effects in various inflammatory diseases, including allergic inflammation, atopic dermatitis, and neuroinflammation [24–26]. Hispidulin has been reported to downregulate LPS-induced inflammatory responses *in vitro* and *in vivo*. Hispidulin inhibits the LPS-induced production of tumor necrosis factor-α, IL-1β, and IL-6 in microglial cells by suppressing the activation of the NF-κB signaling pathway [27]. Additionally, it attenuates LPS-induced acute kidney injury in mice by reducing the expression of pro-inflammatory cytokines and Toll-like receptor 4 (TLR4) and by modulating NF-κB and MAPK signaling pathways [28]. TLR4 signaling plays a crucial role in the

recognition of *P. gingivalis* LPS by endothelial cells, leading to the activation of downstream signaling pathways that ultimately produce pro-inflammatory cytokines and chemokines [29]. Additionally, we observed that hispidulin downregulates *P. gingivalis* LPS-induced mRNA expression of TLR4 in endothelial cells (data not shown). Additionally, we show that hispidulin inhibits the NF- $\kappa$ B, AKT, and MAPKs (ERK, p38 MAPK, and JNK) signaling pathways activated by *P. gingivalis* LPS, along with downstream production of pro-inflammatory cytokines and cell adhesion molecule in vascular endothelial cells. Thus, our results suggest that the negative effect of hispidulin on the inflammatory response triggered by *P. gingivalis* LPS may be due to inhibition of TLR4-dependent signaling pathway.

Recently, natural phenolic compounds capable of modulating host inflammatory responses have received attention as effective tools for managing periodontal disease [5]. Myricetin and apigenin inhibit the expression of inflammatory cytokines and matrix metalloproteinases in different types of cells in the periodontium, such as gingival fibroblasts and periodontal ligament cells [30,31]. Curcumin and quercetin alleviated experimental periodontitis in animal models by reducing gingival inflammation and attenuating alveolar bone loss [32,33]. More recently, oral hygiene products containing *Scutellaria baicalensis* extract or catechins have been shown to decrease the depth and number of bacteria in the periodontal pockets of patients with periodontal disease [34]. Our preliminary results suggest that hispidulin lowers the expression of pro-inflammatory cytokines in human gingival fibroblasts (data not shown), hinting at its anti-inflammatory role in periodontitis. This possibility is currently under investigation.

Atherosclerosis is a chronic inflammatory disease of the arterial wall, leading to plaque formation within the arteries [35]. Vascular endothelial cells, which line the inner surface of blood vessels, are essential for the development and progression of atherosclerosis [36]. Once the endothelial barrier is compromised, inflammatory cells enter the arterial wall and contribute to the formation of atherosclerotic plaques [37]. In this study, we demonstrate that hispidulin reduces monocyte adhesion to *P. gingivalis* LPS-activated endothelial cells and their transmigration across the endothelial layer. The presence of *P. gingivalis* or *P. gingivalis* LPS may be an additional risk factor that exacerbates the progression of atherosclerosis [38]. *P. gingivalis* LPS-accelerated atherosclerosis typically progresses through several stages, including foam cell formation, vascular smooth muscle cell proliferation/migration, plaque rupture, and endothelial dysfunction [39]. Further investigations are ongoing to determine whether hispidulin inhibits several atherosclerotic properties in an established *P. gingivalis* LPS-accelerated atherosclerosis model in ApoE<sup>-/-</sup> mice.

In conclusion, our results show that hispidulin suppresses *P. gingivalis* LPS-induced adhesion and transmigration of monocytes through the vascular endothelium and the expression of pro-inflammatory cytokines and cell adhesion molecule. This is achieved by inhibiting NF- $\kappa$ B and blocking MAPKs and AKT activations. Our findings indicate that hispidulin has beneficial effects in managing and treating periodontal pathogen-associated atherosclerosis.

## 4. Materials and Methods

### 4.1. Reagents and antibodies

Hispidulin and MTT were purchased from Sigma-Aldrich (St. Louis, MO, USA). Antibodies against human ICAM-1 and tubulin were obtained from Santa Cruz Biotechnology (Dallas, TX, USA) and Bioworld Technology (St. Louis Park, MN, USA), respectively. Antibodies against human ERK, phospho-ERK, AKT, phospho-AKT, p38MAPK, phospho-p38MAPK, JNK, and phospho-JNK were acquired from Cell Signaling Technology (Danvers, MA, USA).

### 4.2. Cell culture and osteogenic induction

HUVECs were purchased from CLONETICS (Basel, Switzerland), plated on 0.2 % gelatin-coated dishes, and grown in endothelial cell basal medium-2 (EBM-2; Lonza, Basel, Switzerland) supplemented with EGM-2 SingleQuots™ (Lonza) at 37 °C in humidified air with 5 % CO<sub>2</sub>. HUVECs from passage 2 were seeded at passages 4–7 for subsequent experiments. Human THP-1 monocytes

were purchased from the Korea Cell Line Bank and grown in Roswell Park Memorial Institute (RPMI) 1640 (Gibco, Billings, MT, USA) with 10 % fetal bovine serum (Gibco), 1 % penicillin-streptomycin (Gibco), and 5 µg/mL Plasmocin® (Invitrogen, Carlsbad, CA, USA).

#### 4.3. Cell proliferation assay

HUVECs were seeded in 48-well plates and incubated at 37 °C for 24, 48, or 72 h. At the end of the culture period, the cells were placed in 500 µL fresh medium containing 0.5 mg/mL MTT and incubated for 4 h. The medium was then replaced with 200 µL dimethyl sulfoxide (Sigma-Aldrich) for 3 min. The resulting blue formazan product was measured at 540 nm with a microplate reader (Allsheng, Hangzhou, China).

#### 4.4. Reverse transcription-quantitative PCR

Total RNA was isolated using a RiboEx kit (GeneAll, Seoul, Korea), and reverse-transcribed with a reverse transcription kit (Promega, Madison, WI, USA), followed by real-time PCR with SYBR Green premix (Enzynomix, Daejeon, Korea). The following oligonucleotide primers were used:  $\beta$ -actin 5'-ACTCTTCCAGCCTTCTCC-3' and 5'-TGTTGGCGTACAGGTCTTTG-3'; monocyte chemoattractant protein-1 (MCP-1) 5'-ACTCTCGCTCCAGCATGAA-3' and 5'-TTGATTGCATCTGGCTGAGC-3'; interleukin (IL)-1 $\beta$  5'-GACCTGGACCTCTGCCCTCT-3' and 5'-CTGCCTGAAGCCCTTGCTGT-3'; IL-8 5'-CTGGCCGTGGCTCTCTTG-3' and 5'-CCTTGGCAAACTGCACCTT-3'; ICAM-1 5'-CCCCACCATGAGGACATACA-3' and 5'-GTGTGGGCCTTTGTGTTTG-3'. Cycling parameters included one cycle at 95 °C for 10 min, followed by amplification for 40 cycles at 95 °C for 15 s, 60 °C for 60 s, and 72 °C for 7 s. The process was carried out using an Applied Biosystems thermocycler (Foster City, CA, USA).

#### 4.5. Western immunoblot analysis

Proteins were separated using sodium dodecyl sulfate-polyacrylamide gel electrophoresis and transferred onto a nitrocellulose membrane (Amersham Pharmacia Biotech, Uppsala, Sweden). The membrane was blocked with 5 % skim milk in Tris-buffered saline containing 0.1 % Tween-20 for 1 h at room temperature and probed with the appropriate antibodies. The signal was developed using an enhanced chemiluminescence solution (Amersham Pharmacia Biotech) and visualized on a LAS4000 imager (GE Healthcare Life Sciences, Marlborough, MA, USA).

#### 4.6. Flow cytometry analysis

HUVECs ( $1 \times 10^6$ ) were seeded in a 60-mm dish and incubated with *P. gingivalis* LPS (10 µg/mL) alone or in combination with hispidulin (5 µM) for 16 h. HUVECs were washed with phosphate-buffered saline (PBS) and incubated in PBS with phyco-erythrin-conjugated anti-human CD54 (ICAM-1; BD Biosciences, Bedford, MA, USA) at 4 °C. After 1 h, the cells were washed twice with PBS and analyzed using flow cytometry with a fluorescence-activated cell sorter (BD Biosciences, Franklin Lakes, NJ, USA).

#### 4.7. In vitro monocyte adhesion assay

HUVECs were plated in 24-well plates ( $5 \times 10^4$  cells/well) and incubated with *P. gingivalis* LPS (5 µg/mL) alone or in combination with hispidulin (5 µM) for 16 h. Before their addition, THP-1 cells were stained with 5 g/mL calcein-AM (Invitrogen) for 30 min. THP-1 cells were then added ( $1 \times 10^5$  cells/well) to confluent monolayers of HUVECs and incubated for 1 h. Non-adherent monocytes were removed by washing twice with PBS. Adherent cells were counted in three separate fields in each well under a microscope (Korea Lab Tech, Seungnam, Korea).

#### 4.8. *Ex vivo* monocyte adhesion assay

Male Sprague-Dawley rats (6 weeks of age) were obtained from Koatech (Pyeongtaek, Korea). The aortas were opened longitudinally and incubated with *P. gingivalis* LPS (5 µg/mL) alone or in combination with hispidulin (5 µM) for 16 h. The aortas were then incubated for 1 h with  $5 \times 10^5$  calcein-AM-labeled THP-1 cells. After incubation, unbound monocytes were rinsed twice with PBS. In contrast, adherent cells were counted in three random fields using a fluorescence microscope (Korea Lab Tech).

#### 4.9. Transmigration assay

HUVECs ( $5 \times 10^4$ ) were added in the upper chamber of transwells with 8-µm pore-size membrane inserts (Costar, Corning, NY, USA) and cultured for 24 h to form a confluent monolayer. After incubation, calcein-AM-labeled THP-1 cells were added to the upper chamber and allowed to migrate through the HUVEC monolayer to the lower chamber for 24 h. These cells were treated with *P. gingivalis* LPS (5 g/mL) alone or in combination with hispidulin (5 µM) in EBM-2 medium supplemented with EGM-2 SingleQuots™. The lower chamber was filled with RPMI 1640 medium. Images were captured using a fluorescence microscope (Korea Lab Tech). Each experiment was performed in duplicate, and three separate experiments were performed for each group.

#### 4.10. Transient transfection and reporter gene analysis

HUVECs were transfected with 3 µg of the plasmid DNA using Amaxa Nucleofector II (Lonza). After transfection, HUVECs were incubated with *P. gingivalis* LPS (5 µg/mL) alone or in combination with hispidulin (5 µM) for 16 h. The cell extracts were analyzed using a β-galactosidase enzyme assay (Promega) for the luciferase activity using a luminometer (Turner Biosystems, Sunnyvale, CA, USA). The relative luciferase activity was calculated as RLU/β-galactosidase at least three times. The ICAM-1 luciferase reporter constructs with the full-length (-1350 to +45 bp) and truncated forms (-485 to +45 bp) were used as previously described [20].

#### 4.11. Immunocytochemistry

HUVECs were pretreated with hispidulin (5 µM) for 30 min, incubated for 1 h with *P. gingivalis* LPS (5 g/mL), and fixed in 4 % paraformaldehyde. After blocking with 0.5 % Triton X-100/PBS and 5 % normal goat serum (Vector Labs, Burlingame, CA, USA), the cells were reacted with primary antibody against NF-κB p65 (Santa Cruz Biotechnology) and Alexa® 488-conjugated secondary antibody for 1 h. Coverslips were mounted with DAPI-containing Vectastain (Vector Laboratories). Cells were analyzed using a confocal microscope (LSM900; Zeiss, Oberkochen, Germany).

#### 4.12. Statistical analysis

Data represent the mean and standard deviation of at least three independent experiments. Data were subjected to one-way analysis of variance with Tukey's honest significant difference post-hoc test and Student's t-test.

**Author Contributions:** Conceptualization, M.-K.B.; methodology, H.-J.P., M.-K.K. and Y.K.; resources, H.-J.K., H.L. and Y.-I. K.; investigation, H.-J.P., Y.K., H.L. and M.-K.K.; data curation, H.-J.P. and Y.K.; formal analysis, H.L. and S.-K.B.; writing—original draft, Y.K. and M.-K.B.; writing—review and editing, H.L., Y.-J.K. and M.-K.B.; funding acquisition, M.-K.B.; project administration, Y.-J.K. and M.-K.B.; supervision, Y.-J.K. and M.-K.B.

**Acknowledgments:** This research was supported by a grant from the National Research Foundation of Korea, funded by the Korean government (MSIT, NRF-2018R1A5A2023879) and (No. 2021R1A2C1003687).

**Conflicts of Interest:** The authors deny any conflict of interest related to this study.

## References

- Sharaf, S.; Hijazi, K. Modulatory Mechanisms of Pathogenicity in *Porphyromonas Gingivalis* and Other Periodontal Pathobionts. *Microorganisms* **2022**, *11*, 15. <https://doi.org/10.3390/microorganisms11010015>.
- Mysak, J.; Podzimek, S.; Sommerova, P.; Lyuya-Mi, Y.; Bartova, J.; Janatova, T.; Prochazkova, J.; Duskova, J. *Porphyromonas Gingivalis*: Major Periodontopathogenic Pathogen Overview. *J. Immunol. Res.* **2014**, 476068. <https://doi.org/10.1155/2014/476068>.
- Jia, G.; Zhi, A.; Lai, P.F.H.; Wang, G.; Xia, Y.; Xiong, Z.; Zhang, H.; Che, N.; Ai, L. The Oral Microbiota - a Mechanistic Role for Systemic Diseases. *Br. Dent. J.* **2018**, *224*, 447-455.
- Kholy, K.E.; Genco, R.J.; Van Dyke, T.E. Oral Infections and Cardiovascular Disease. *Trends Endocrinol. Metab.* **2015**, *26*, 315-321. <https://doi.org/10.1111/prd.12393>.
- Fernández-Rojas, B.; Gutiérrez-Venegas, G. Flavonoids Exert Multiple Periodontic Benefits Including Anti-Inflammatory, Periodontal Ligament-Supporting, and Alveolar Bone-Preserving Effects. *Life Sci.* **2018**, *209*, 435-454. <https://doi.org/10.1016/j.lfs.2018.08.029>.
- Cai, Y.; Kurita-Ochiai, T.; Hashizume, T.; Yamamoto, M. Green Tea Epigallocatechin-3-Gallate Attenuates *Porphyromonas Gingivalis*-Induced Atherosclerosis. *Pathog. Dis.* **2013**, *67*, 76-83. <https://doi.org/10.1111/2049-632X.12001>.
- Liu, K.; Zhao, F.; Yan, J.; Xia, Z.; Jiang, D.; Ma, P. Hispidulin: A Promising Flavonoid with Diverse Anti-Cancer Properties. *Life Sci.* **2020**, *259*, 118395. <https://doi.org/10.1016/j.lfs.2020.118395>.
- Ashaq, A.; Maqbool, M.F.; Maryam, A.; Khan, M.; Shakir, H.A.; Irfan, M.; Qazi, J.I.; Li, Y.; Ma, T. Hispidulin: A Novel Natural Compound with Therapeutic Potential Against Human Cancers. *Phytother. Res.* **2021**, *35*, 771-789. <https://doi.org/10.1002/ptr.6862>.
- Patel, K.; Patel, D.K. Medicinal Importance, Pharmacological Activities, and Analytical Aspects of Hispidulin: A Concise Report. *J. Tradit. Complement. Med.* **2016**, *7*, 360-366. <https://doi.org/10.1016/j.jtcme.2016.11.003>.
- Zhou, R.; Wang, Z.; Ma, C. Hispidulin Exerts Anti-Osteoporotic Activity in Ovariectomized Mice Via Activating AMPK Signaling Pathway. *Cell Biochem. Biophys.* **2014**, *69*, 311-317.
- Kim, D.E.; Min, K.J.; Kim, M.J.; Kim, S.H.; Kwon, T.K. Hispidulin Inhibits Mast Cell-Mediated Allergic Inflammation through Down-Regulation of Histamine Release and Inflammatory Cytokines. *Molecules* **2019**, *24*, 2131. <https://doi.org/10.3390/molecules24112131>.
- Kim, N.; Lee, S.; Kang, J.; Choi, Y.A.; Lee, B.; Kwon, T.K.; Jang, Y.H.; Kim, S.H. Hispidulin Alleviates Imiquimod-Induced Psoriasis-Like Skin Inflammation by Inhibiting Splenic Th1/Th17 Cell Population and Keratinocyte Activation. *Int. Immunopharmacol.* **2020**, *87*, 106767. <https://doi.org/10.1016/j.intimp.2020.106767>.
- He, L.; Wu, Y.; Lin, L.; Wang, J.; Wu, Y.; Chen, Y.; Yi, Z.; Liu, M.; Pang, X. Hispidulin, a Small Flavonoid Molecule, Suppresses the Angiogenesis and Growth of Human Pancreatic Cancer by Targeting Vascular Endothelial Growth Factor Receptor 2-Mediated PI3K/Akt/mTOR Signaling Pathway. *Cancer Sci.* **2011**, *102*, 219-225. <https://doi.org/10.1111/j.1349-7006.2010.01778.x>.
- Taleb, S. Inflammation in Atherosclerosis. *Arch. Cardiovasc. Dis.* **2016**, *109*, 708-715. <http://dx.doi.org/10.1016/j.acvd.2016.04.002>.
- Davies, M.J.; Gordon, J.L.; Gearing, A.J.; Pigott, R.; Woolf, N.; Katz, D.; Kyriakopoulos, A. The Expression of the Adhesion Molecules ICAM-1, VCAM-1, PECAM, and E-Selectin in Human Atherosclerosis. *J. Pathol.* **1993**, *171*, 223-229. <https://doi.org/10.1002/path.1711710311>.
- Park, H.J.; Jeong, S.K.; Kim, S.R.; Bae, S.K.; Kim, W.S.; Jin, S.D.; Koo, T.H.; Jang, H.Y.; Yun, I.; Kim, K.W.; Bae, M.K. Resveratrol Inhibits *Porphyromonas Gingivalis* Lipopolysaccharide-Induced Endothelial Adhesion Molecule Expression by Suppressing NF-kappaB Activation. *Arch. Pharm. Res.* **2009**, *32*, 583-591.
- Toriuchi, K.; Kihara, T.; Aoki, H.; Kakita, H.; Takeshita, S.; Ueda, H.; Inoue, Y.; Hayashi, H.; Shimono, Y.; Yamada, Y.; Aoyama, M. Monocyte-Derived miRNA-1914-5p Attenuates IL-1 $\beta$ -Induced Monocyte Adhesion and Transmigration. *Int. J. Mol. Sci.* **2023**, *24*, 2829. <https://doi.org/10.3390/ijms24032829>.
- Fenyo, I.M.; Gafencu, A.V. The Involvement of the Monocytes/Macrophages in Chronic Inflammation Associated with Atherosclerosis. *Immunobiology* **2013**, *218*, 1376-1384. <http://dx.doi.org/10.1016/j.imbio.2013.06.005>.
- Verma, I. Nuclear Factor (NF)-kappaB Proteins: Therapeutic Targets. *Ann. Rheum. Dis.* **2004**, *63 Suppl 2*, ii57-ii61. <http://dx.doi.org/10.1136/ard.2004.028266>.
- Kim, S.R.; Bae, Y.H.; Bae, S.K.; Choi, K.S.; Yoon, K.H.; Koo, T.H.; Jang, H.O.; Yun, I.; Kim, K.W.; Kwon, Y.G.; Yoo, M.A.; Bae, M.K. Visfatin Enhances ICAM-1 and VCAM-1 Expression through ROS-Dependent NF-kappaB Activation in Endothelial Cells. *Biochim. Biophys. Acta* **2008**, *1783*, 886-895. <https://doi.org/10.1016/j.bbamcr.2008.01.004>.
- Zhu, J.; Cynader, M.; Jia, W. TDP-43 Inhibits NF-kB Activity by Blocking p65 Nuclear Translocation. *PLoS One* **2015**, *10*, e0142296. <https://doi.org/10.1371/journal.pone.0142296>.

22. Jian, C.X.; Li, M.Z.; Zheng, W.Y.; He, Y.; Ren, Y.; Wu, Z.M.; Fan, Q.S.; Hu, Y.H.; Li, C.J. Tormentic Acid Inhibits LPS-Induced Inflammatory Response in Human Gingival Fibroblasts Via Inhibition of TLR4-Mediated NF- $\kappa$ B and MAPK Signalling Pathway. *Arch. Oral Biol.* **2015**, *60*, 1327-1332. <http://dx.doi.org/10.1016/j.archoralbio.2015.05.005>.
23. Yilmaz, O.; Jungas, T.; Verbeke, P.; Ojcius, D.M. Activation of the Phosphatidylinositol 3-Kinase/Akt Pathway Contributes to Survival of Primary Epithelial Cells Infected with the Periodontal Pathogen *Porphyromonas Gingivalis*. *Infect. Immun.* **2004**, *72*, 3743-3751. <https://doi.org/10.1128/iai.72.7.3743-3751.2004>.
24. An, P.; Xie, J.; Qiu, S.; Liu, Y.; Wang, J.; Xiu, X.; Li, L.; Tang, M. Hispidulin Exhibits Neuroprotective Activities Against Cerebral Ischemia Reperfusion Injury through Suppressing NLRP3-Mediated Pyroptosis. *Life Sci.* **2019**, *232*, 116599. <https://doi.org/10.1016/j.lfs.2019.116599>.
25. Dabaghi-Barbosa, P.; Mariante Rocha, A.; Franco da Cruz Lima, A.; Heleno de Oliveira, B.; Benigna Martinelli de Oliveira, M.; Gunilla Skare Carnieri, E.; Cadena, S.M.S.C.; Eliane Merlin Rocha, M. Hispidulin: Antioxidant Properties and Effect on Mitochondrial Energy Metabolism. *Free Radic. Res.* **2005**, *39*, 1305-1315. <https://doi.org/10.1080/13561820500177659>.
26. Kang, J.; Lee, S.; Kim, N.; Dhakal, H.; Choi, Y.A.; Kwon, T.K.; Khang, D.; Kim, S.H. Hispidulin Alleviates 2,4-Dinitrochlorobenzene and House Dust Mite Extract-Induced Atopic Dermatitis-Like Skin Inflammation. *Biomed. Pharmacother.* **2021**, *137*, 111359. <https://doi.org/10.1016/j.biopha.2021.111359>.
27. Yu, C.; Cheng, C.; Kang, Y.F.; Chang, P.C.; Lin, I.P.; Kuo, Y.H.; Jhou, A.J.; Lin, M.Y.; Chen, C.Y.; Lee, C.H. Hispidulin Inhibits Neuroinflammation in Lipopolysaccharide-Activated BV2 Microglia and Attenuates the Activation of Akt, NF- $\kappa$ B, and STAT3 Pathway. *Neurotox Res.* **2020**, *38*, 163-174.
28. Kim, K.; Leem, J. Hispidulin Ameliorates Endotoxin-Induced Acute Kidney Injury in Mice. *Molecules* **2022**, *27*, 2019. <https://doi.org/10.3390/molecules27062019>.
29. Nativel, B.; Couret, D.; Giraud, P.; Meilhac, O.; d'Hellencourt, C.L.; Viranaïcken, W.; Da Silva, C.R. *Porphyromonas Gingivalis* Lipopolysaccharides Act Exclusively through TLR4 with a Resilience between Mouse and Human. *Sci. Rep.* **2017**, *7*, 15789. <https://doi.org/10.1038/s41598-017-16190-y>.
30. Gutiérrez-Venegas, G.; Alonso Luna, O.; Ventura-Arroyo, J.A.; Hernández-Bermúdez, C. Myricetin Suppresses Lipoteichoic Acid-Induced Interleukin-1 $\beta$  and Cyclooxygenase-2 Expression in Human Gingival Fibroblasts. *Microbiol. Immunol.* **2013**, *57*, 849-856. <https://doi.org/10.1111/1348-0421.12103>.
31. Jeong, G.S.; Lee, S.H.; Jeong, S.N.; Kim, Y.C.; Kim, E.C. Anti-Inflammatory Effects of Apigenin on Nicotine- and Lipopolysaccharide-Stimulated Human Periodontal Ligament Cells Via Heme Oxygenase-1. *Int. Immunopharmacol.* **2009**, *9*, 1374-1380. <https://doi.org/10.1016/j.intimp.2009.08.015>.
32. Yetkin Ay, Z.; Bakır, B.; Bozkurt, S.B.; Kayis, S.A.; Hakki, S.S. Positive Effect of Curcumin on Experimental Periodontitis Via Suppression of IL-1-Beta and IL-6 Expression Level. *Int. J. Vitam. Nutr. Res.* **2022**, *92*, 231-239. <https://doi.org/10.1024/0300-9831/a000672>.
33. Cheng, W.C.; Huang, R.Y.; Chiang, C.Y.; Chen, J.K.; Liu, C.H.; Chu, C.L.; Fu, E. Ameliorative Effect of Quercetin on the Destruction Caused by Experimental Periodontitis in Rats. *J. Periodontal. Res.* **2010**, *45*, 788-795. <https://doi.org/10.1111/j.1600-0765.2010.01301.x>.
34. Ming, J.; Zhuoneng, L.; Guangxun, Z. Protective Role of Flavonoid Baicalin from *Scutellaria Baicalensis* in Periodontal Disease Pathogenesis: A Literature Review. *Complement. Ther. Med.* **2018**, *38*, 11-18. <https://doi.org/10.1016/j.ctim.2018.03.010>.
35. Tabas, I.; García-Cardena, G.; Owens, G.K. Recent Insights into the Cellular Biology of Atherosclerosis. *J. Cell Biol.* **2015**, *209*, 13-22. <https://doi.org/10.1083/jcb.201412052>.
36. Dri, E.; Lampas, E.; Lazaros, G.; Lazarou, E.; Theofilis, P.; Tsioufis, C.; Tousoulis, D. Inflammatory Mediators of Endothelial Dysfunction. *Life. (Basel)* **2023**, *13*, 1420. <https://doi.org/10.3390/life13061420>.
37. Libby, P.; Ridker, P.M.; Hansson, G.K.; Leducq Transatlantic Network on Atherothrombosis. Inflammation in Atherosclerosis: From Pathophysiology to Practice. *J. Am. Coll. Cardiol.* **2009**, *54*, 2129-2138. <https://doi.org/10.1016/j.jacc.2009.09.009>.
38. Li, L.; Bian, T.; Lyu, J.; Cui, D.; Lei, L.; Yan, F. Human B-Defensin-3 Alleviates the Progression of Atherosclerosis Accelerated by *Porphyromonas Gingivalis* Lipopolysaccharide. *Int. Immunopharmacol.* **2016**, *38*, 204-213. <https://doi.org/10.1016/j.intimp.2016.06.003>.
39. Chistiakov, D.A.; Orekhov, A.N.; Bobryshev, Y.V. Links between Atherosclerotic and Periodontal Disease. *Exp. Mol. Pathol.* **2016**, *100*, 220-235. <https://doi.org/10.1016/j.yexmp.2016.01.006>.

**Disclaimer/Publisher's Note:** The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.